Novel insights in animal vaccines

  E-mail   Print

Editors:
César B. Gutiérrez Martín, Sonia Martínez Martínez and Elías F. Rodríguez Ferri. Section of Microbiology and Immunology, Department of Animal Health, Faculty of Veterinary Medicine, University of León, Spain

Introduction of the special issue

Vaccination continues to be the cheapest and most efficient method of preventing infectious diseases not only in humans but also in domestic animals. Vaccines induce the activation of adaptive immunity, both cellular and humoral responses. The oldest vaccines were composed of killed or attenuated whole pathogens. However, over the past few decades, vaccine technology has advanced quickly, which has been possible through the finding of modern molecular techniques and through the emerging understanding of immune mechanisms. This has led to the development of several new types of vaccines, capable of achieving a better protection with a substantially lesser amount of adverse effects and being safer than the traditional killed or modified live vaccines.
On the other hand, vaccine efficacy has been greatly improved over the years by the use of adjuvants which are substances that increase the speed or the extent of the body’s response to immunogens. For a long time, most adjuvants cause adverse effects especially related to strong inflammatory reactions. However, consistent with the development of novel vaccine technologies has occurred the development of new safer adjuvants, all of this greatly enhancing the efficacy of modern vaccines. Among these innovative molecular techniques, DNA vaccines, structural or reverse vaccinologies can be cited. These vaccines can circumvent several of the problems intrinsic to traditional vaccines and optimize the efficacy against infectious diseases for which current vaccines have little effect or are not available.

Potential topics but are not restricted to:
•     Use of old or novel adjuvants in achieving better protection with vaccines
•     Vaccines based on live or dead organisms
•     Vaccines based on genetically attenuated organisms
•     Vaccines based on live recombinant organisms
•     DNA vaccination
•     RNA vaccination
•     Reverse vaccinology

Submitted papers should not have been published nor be currently under consideration for publication elsewhere. All manuscripts will be peer-reviewed before their acceptance for publication. Accepted articles will be published in AIMS Allergy and Immunology open access free of charge. The deadline for manuscript submission is June 30, 2018.

Instruction for Authors:
http://www.aimspress.com/news/217.html

Please submit your manuscript to online submission system
http://oeps.aimspress.com/allergy/ch/author/login.aspx

Elías Fernando Rodríguez Ferri, Sonia Martínez Martínez, César Bernardo Gutiérrez Martín
+ Abstract     + HTML     + PDF(306 KB)
Open Access Journals
Blog:
More
Open Access Journals